Mikhail P. Semenov

Moscow, MOW, Russian Federation

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 9 publications

Fortelyzin in the treatment of acute ischemic stroke in patients ≥80 years old: data from the observational study FORPI registry

Fortelyzin in the treatment of acute ischemic stroke in patients ≥80 years old: data from the observational study FORPI registry

Journal: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova

Published: April 15, 2026

Fortelizin in bridging therapy of acute ischemic stroke: data from the observational study FORPI registry

Fortelizin in bridging therapy of acute ischemic stroke: data from the observational study FORPI registry

Journal: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova

Published: March 05, 2026

Fortelyzin for acute ischaemic stroke treatment in an extended (4.5 to 24 hours from the onset of symptoms) time window: data from the observational study FORPI registry

Fortelyzin for acute ischaemic stroke treatment in an extended (4.5 to 24 hours from the onset of symptoms) time window: data from the observational study FORPI registry

Journal: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova

Published: February 09, 2026

Fortelyzin for acute ischaemic stroke treatment: an open, prospective, non-interventional, observational study FORPI registry

Fortelyzin for acute ischaemic stroke treatment: an open, prospective, non-interventional, observational study FORPI registry

Journal: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova

Published: January 12, 2026

Thrombolysis With the Non-Immunogenic Staphylokinase for Acute Ischemic Stroke in the FORPI Registry: An Observational Study.

Thrombolysis With the Non-Immunogenic Staphylokinase for Acute Ischemic Stroke in the FORPI Registry: An Observational Study.

Journal: Stroke

Published: November 26, 2025

Prognostic outcome of intravenous thrombolysis with non-immunogenic staphylokinase in patients aged ≥ 60 years with acute ischemic stroke by THRIVE scale.

Prognostic outcome of intravenous thrombolysis with non-immunogenic staphylokinase in patients aged ≥ 60 years with acute ischemic stroke by THRIVE scale.

Journal: Journal of thrombosis and thrombolysis

Published: December 26, 2024

Intraarterial intrathrombus thrombolysis with non-immunogenic staphylokinase vs surgery in patients with acute limb ischemia: protocol of a multicenter, open-label, randomized clinical trial FORAT

Intraarterial intrathrombus thrombolysis with non-immunogenic staphylokinase vs surgery in patients with acute limb ischemia: protocol of a multicenter, open-label, randomized clinical trial FORAT

Journal: Angiologiia i sosudistaia khirurgiia = Angiology and vascular surgery

Published: October 08, 2024

Nonimmunogenic staphylokinase in the treatment of acute ischemic stroke (FRIDA trial results)

Nonimmunogenic staphylokinase in the treatment of acute ischemic stroke (FRIDA trial results)

Journal: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova

Published: July 29, 2022

Nebulized Non-Immunogenic Staphylokinase in the Mice Acute Lung Injury Model.

Nebulized Non-Immunogenic Staphylokinase in the Mice Acute Lung Injury Model.

Journal: International journal of molecular sciences

Published: July 19, 2022

Showing 1-9 of 9

Last Updated: 09/26/2026